ENTREMED, INC. (NASDAQ:ENMD)
| CAPS Rating |
|
|---|---|
| Open | $2.39 |
| Previous Close | $2.44 |
| Daily Range | $2.35 - $2.70 |
| 52-Week Range | $0.90 - $5.55 |
| Market Cap | $31.70M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 71,174 |
| Average Daily Volume | 0 |
ENMD
VS S&P 500 (SPY)
This ticker is not currently Ratable.
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
ENMD Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
ENMD News and Commentary
- EntreMed: Low Share Count, Multiple Upcoming Catalysts – SeekingAlpha
- China Biotech Week in Review: Shanghai Pharma Plans $1.2 Billion IPO – SeekingAlpha
- Big Pharma Looks to Biotech for Innovation – SeekingAlpha
- EntreMed Sweetens Private Placement With China Rights to Cancer Drug – SeekingAlpha
- EntreMed Widens Loss in 2Q, Clinical Trials for Ovarian Cancer Progress – Fox Business
- Why We Love Wild Penny Stocks – The Motley Fool
- The Best Stocks for the Next 4 Years – The Motley Fool
- Closing ENMD (Entremed) underperform – Blog at The Motley Fool
- 7 Surprising 5-Star Stocks – The Motley Fool
- 5 More Top Small Caps – The Motley Fool
- Are You a Venture Capitalist? – The Motley Fool
- Golden Years, Golden Wealth – The Motley Fool
Related News and Articles
- Illuminating the Way Forward for Genomics – The Motley Fool
- When Passing Your Clinical Trial Isn't Enough – The Motley Fool
- This Just In: More Upgrades and Downgrades – The Motley Fool
- Life Technologies' Sequence of Success – The Motley Fool
- Is Avanir Pharmaceuticals the Perfect Stock? – The Motley Fool
- Can Amgen Convince Docs to Recommend Approval? – The Motley Fool
RSS Headlines
Fool UK
